Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial.
Dent RA, Kim SB, Oliveira M, Barrios C, O'Shaughnessy J, Isakoff SJ, Saji S, Freitas-Junior R, Philco M, Bondarenko I, Lian Q, Bradley D, Hinton H, Wongchenko MJ, Reilly SJ, Turner N. Dent RA, et al. Among authors: freitas junior r. Clin Cancer Res. 2024 Oct 1;30(19):4329-4338. doi: 10.1158/1078-0432.CCR-24-0465. Clin Cancer Res. 2024. PMID: 39058425 Free PMC article. Clinical Trial.
Reply to: Mastectomy skin flap thickness.
Marta GN, Poortmans P, de Barros AC, Filassi JR, Freitas-Junior R, Audisio RA, Mano MS, Meterissian S, DeSnyder SM, Buchholz TA, Hijal T. Marta GN, et al. Eur J Surg Oncol. 2018 Jul;44(7):1119-1120. doi: 10.1016/j.ejso.2018.04.009. Epub 2018 Apr 27. Eur J Surg Oncol. 2018. PMID: 29739639 No abstract available.
Cytology by capillary.
Freitas Júnior R. Freitas Júnior R. Rev Paul Med. 1993 Jan-Feb;111(1):336. Rev Paul Med. 1993. PMID: 8235255 No abstract available.
First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results.
Schmid P, Turner NC, Barrios CH, Isakoff SJ, Kim SB, Sablin MP, Saji S, Savas P, Vidal GA, Oliveira M, O'Shaughnessy J, Italiano A, Espinosa E, Boni V, White S, Rojas B, Freitas-Junior R, Chae Y, Bondarenko I, Lee J, Torres Mattos C, Martinez Rodriguez JL, Lam LH, Jones S, Reilly SJ, Huang X, Shah K, Dent R. Schmid P, et al. Clin Cancer Res. 2024 Feb 16;30(4):767-778. doi: 10.1158/1078-0432.CCR-23-2084. Clin Cancer Res. 2024. PMID: 38060199 Free PMC article. Clinical Trial.
Phase II trial of humanized anti-Lewis Y monoclonal antibody for advanced hormone receptor-positive breast cancer that progressed following endocrine therapy.
Testa L, Mano M, Arai RJ, Bonadio RC, Serrano SV, Zorzetto MMC, Crocamo S, Smaletz O, Freitas-Junior R, Hoff PM. Testa L, et al. Clinics (Sao Paulo). 2021 Oct 11;76:e3146. doi: 10.6061/clinics/2021/e3146. eCollection 2021. Clinics (Sao Paulo). 2021. PMID: 34644735 Free PMC article. Clinical Trial.
The neutrophil-to-lymphocyte ratio: a narrative review.
Faria SS, Fernandes PC Jr, Silva MJ, Lima VC, Fontes W, Freitas-Junior R, Eterovic AK, Forget P. Faria SS, et al. Ecancermedicalscience. 2016 Dec 12;10:702. doi: 10.3332/ecancer.2016.702. eCollection 2016. Ecancermedicalscience. 2016. PMID: 28105073 Free PMC article. Review.
124 results